Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	20.4	20.01	22.99	19.36	49.65	48.08
Cash & Short-Term Investments	20.4	20.01	22.99	19.36	49.65	48.08
Cash Growth	4.45%	-12.96%	18.72%	-61.01%	3.26%	335.36%
Receivables	25.4	23.62	28.94	21.71	28.18	5.63
Inventory	11.09	12.63	12	10.85	16.34	10
Prepaid Expenses	6.17	5.64	7.16	7.38	9.78	5.72
Restricted Cash	-	-	-	-	0.25	0.25
Other Current Assets	-	-	-	0.63	1.04	5.74
Total Current Assets	63.05	61.89	71.08	59.93	105.23	75.42
Property, Plant & Equipment	1.69	1.52	3.87	6.3	8.7	0.89
Goodwill	-	-	-	-	65.8	28.09
Other Intangible Assets	49.96	52.45	58.97	70.63	85.46	48.86
Long-Term Deferred Tax Assets	-	0.76	1.38	-	-	-
Other Long-Term Assets	1.52	1.47	1.17	0.77	0.47	0.03
Total Assets	116.23	118.1	136.46	137.62	265.67	153.29
Accounts Payable	11.7	10.44	13.48	10.99	19.26	11.64
Accrued Expenses	19.75	22.69	25.28	25.71	30.72	10.3
Short-Term Debt	4.01	2.4	1.56	3.81	7.93	-
Current Portion of Long-Term Debt	1.86	1.86	-	-	16.57	0.98
Current Portion of Leases	0.18	0.71	1.34	0.1	0.1	0.3
Other Current Liabilities	26.54	24.14	27.35	23.84	34.86	5.54
Total Current Liabilities	64.05	62.23	69.02	64.44	109.44	28.76
Long-Term Debt	9.98	10.88	14.71	14.2	-	-
Long-Term Leases	1.11	0.58	0.83	0.08	0.18	0.73
Long-Term Deferred Tax Liabilities	-	0.76	1.38	-	-	-
Other Long-Term Liabilities	10.33	15.94	11.17	14.59	18.48	28.79
Total Liabilities	85.46	90.38	97.11	93.32	128.1	58.28
Common Stock	0	0	0	-	0	0
Additional Paid-In Capital	348.48	347.69	343.49	331.39	315.86	215.02
Retained Earnings	-317.71	-319.97	-304.13	-287.08	-178.3	-120.01
Total Common Equity	30.77	27.72	39.36	44.31	137.57	95.02
Shareholders' Equity	30.77	27.72	39.36	44.31	137.57	95.02
Total Liabilities & Equity	116.23	118.1	136.46	137.62	265.67	153.29
Total Debt	17.14	16.42	18.45	18.19	24.78	2.01
Net Cash (Debt)	3.26	3.59	4.53	1.17	24.87	46.08
Net Cash Growth	156.13%	-20.86%	286.86%	-95.29%	-46.03%	317.19%
Net Cash Per Share	0.56	0.65	1.36	0.80	29.70	203.91
Filing Date Shares Outstanding	6.17	6.15	5.53	3.12	1.38	0.63
Total Common Shares Outstanding	6.17	5.97	5.52	1.93	1.37	0.63
Working Capital	-1	-0.34	2.06	-4.51	-4.2	46.66
Book Value Per Share	4.99	4.64	7.13	22.97	100.08	151.01
Tangible Book Value	-19.19	-24.74	-19.61	-26.32	-13.7	18.07
Tangible Book Value Per Share	-3.11	-4.14	-3.55	-13.65	-9.97	28.72
Machinery	1	2.78	4.39	4.45	5	0.51
Construction In Progress	-	-	0.11	-	0.2	-
Leasehold Improvements	0.16	0.04	1	1	0.96	0.23

Source: S&P Capital IQ. Standard template. Financial Sources.